BDX Stock Overview
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
BCAL Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.06 |
| 52 Week High | AU$0.15 |
| 52 Week Low | AU$0.059 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -9.09% |
| 1 Year Change | -42.86% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.00% |
Recent News & Updates
Shareholder Returns
| BDX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.6% |
| 1Y | -42.9% | 11.8% | 3.5% |
Return vs Industry: BDX underperformed the Australian Biotechs industry which returned 11.8% over the past year.
Return vs Market: BDX underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: Insufficient data to determine BDX's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine BDX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | John Hurrell | https://www.bcaldiagnostics.com |
BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient’s body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market Cap | AU$12.69m |
| Earnings (TTM) | -AU$3.39m |
| Revenue (TTM) | AU$718.67k |
17.7x
P/S Ratio-3.7x
P/E RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | AU$718.67k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$718.67k |
| Other Expenses | AU$4.10m |
| Earnings | -AU$3.39m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 100.00% |
| Net Profit Margin | -471.08% |
| Debt/Equity Ratio | 0% |
How did BDX perform over the long term?
See historical performance and comparison